Clinical Trials Browser

Phase 2 × Unknown × Thoracic × Clear all

NCT05599789 2025-02-18

KeyPemls-004

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06586697 2024-09-19

First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT04922658 2024-07-31

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Phase 2 Unknown

Advanced Non-Small Cell Lung Cancer

NCT03921671 2024-05-29

RELEVENT

Phase 2 Unknown

Neoplasm Metastasis, Thymoma

NCT06406673 2024-05-09

A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Phase 2 Unknown

Extensive Small Cell Lung Cancer

NCT06341530 2024-04-02

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06341660 2024-04-02

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06339242 2024-04-01

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Phase 2 Unknown

NSCLC

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase 2 Unknown

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT06334757 2024-03-28

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Phase 2 Unknown

Non-Squamous Non-Small Cell Lung Cancer

NCT06332287 2024-03-27

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis

Phase 2 Unknown

NSCLC

NCT06331650 2024-03-26

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06328049 2024-03-25

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Phase 2 Unknown

NSCLC

NCT05801133 2024-03-15

Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors

Phase 2 Unknown

Lung Neoplasms

NCT05004974 2024-03-12

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

Advanced Non Small Cell Lung Cancer

NCT06277674 2024-03-08

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03865511 2024-02-28

MELROSE

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06279754 2024-02-28

Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy

Phase 2 Unknown

Locally Advanced Squamous Non-small Cell Lung Cancer

NCT03924466 2024-02-16

VUBAR

Phase 2 Unknown

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT01871454 2024-02-07

Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers

Phase 2 Unknown

Non-small Cell Lung Cancers

NCT05946460 2024-02-06

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Phase 2 Unknown

Lung Neoplasms

NCT06101394 2024-01-25

RECOGNISE

Phase 2 Unknown

Lung Neoplasms

NCT05092412 2024-01-12

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Phase 2 Unknown

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05296278 2024-01-10

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05296603 2024-01-10

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT06195683 2024-01-08

NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04937972 2023-12-29

FLYFLY

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05611879 2023-12-29

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02098954 2023-12-27

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03646968 2023-12-27

SAVE

Phase 2 Unknown

Non-Squamous Non Small Cell Lung Cancer

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05329025 2023-11-24

A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05812534 2023-11-18

CBC

Phase 2 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05311709 2023-11-09

SOLUCOM

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04467801 2023-11-07

Ipat-Lung

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05863325 2023-11-07

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06108726 2023-10-31

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

Phase 2 Unknown

NSCLC

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04726215 2023-09-29

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04074993 2023-09-28

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05128630 2023-09-28

DEDALUS

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05228496 2023-09-26

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT06019468 2023-09-06

Neoadjuvant Treatment For Locally Advanced Thymic Cancer

Phase 2 Unknown

Thymoma

NCT05338619 2023-09-01

PLATINUM

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06020989 2023-09-01

CHAMELEON

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05869162 2023-08-25

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03215693 2023-08-16

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05987826 2023-08-14

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05932264 2023-07-06

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05203276 2023-06-22

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Phase 2 Unknown

Lung Neoplasms